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COMMENTARY Open Access
The definition and classification of
pneumonia
Grant Mackenzie1,2,3
Abstract
Following the publication of a volume of Pneumonia focused on diagnosis, the journal’s Editorial Board members
debated the definition and classification of pneumonia and came to a consensus on the need to revise both of
these. The problem with our current approach to the classification of pneumonia is twofold: (i) it results in
widespread empirical, and often unnecessary, use of antimicrobials that contributes to pathogen resistance; and (ii)
it contributes to heterogeneity among the groups of subjects compared in research, causing misclassification bias
and mixtures of effects that threaten internal validity. After outlining the problem of classification, this commentary
describes the strengths and weaknesses of a range of systems for the classification of pneumonia. The commentary
then calls for debate to generate consensus classifications in the field, proposing a working definition and way
forward focusing on the following three points: (i) pneumonia should be defined as an acute infection of the lung
parenchyma by various pathogens, excluding the condition of bronchiolitis; (ii) defining pneumonia as a group
of specific (co)infections with different characteristics is an ideal that currently has limited use, because the
identification of aetiologic organisms in individuals is often not possible (however, the benefits of classifying
pneumonia into specific, more homogenous phenotypes should be carefully considered when designing research
studies); and (iii) investigation of more homogenous pneumonia groupings is achievable and is likely to yield
more rapid advances in the field.
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Background
Volume 5 of Pneumonia was a theme issue on the diag-
nosis of pneumonia. Papers focused on the diagnostic
roles of chest radiography [1], rapid analysis of biological
samples [2], severity scores [3], and the electronic collec-
tion of multiple clinical input data with rapid algorith-
mic analysis [4]. An ensuing discussion between some of
the Pneumonia Editorial Board members reflected on
the lack of clarity around the definition and classification
of pneumonia in the published papers and in the field of
pneumonia research.
Summary of opinions from the editorial board
discussion
A number of members of the Pneumonia Editorial Board
engaged in a discussion and were in agreement that the
lack of an accepted and widely used definition or classifi-
cation of pneumonia is a significant problem. However,
there was less agreement on how pneumonia should be
defined and classified and how this issue should be tack-
led. Perspectives from high-income settings included the
poor correlation between radiologic appearance and sys-
tems for International Classification of Disease (ICD) for
hospital admissions, and an appeal for a definition that
recognises certain aspects particular to older adults. The
diagnosis of pneumonia in the intensive care setting was
noted as being particularly unreliable, although the
evolving use of lung ultrasound offers more clarity. It
was argued that the popular use of the term, ‘commu-
nity-acquired pneumonia’ does little to advance our un-
derstanding of the condition. The medical literature
includes the term ‘pneumonia’ or ‘pneumonitis’ in a col-
lection of diagnostic terms for a number of conditions
that are not related to infection or have an unknown
cause, which illustrates the lack of consensus in the def-
inition of pneumonia. The Editorial Board members who
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participated in the discussion would most likely agree
that pneumonia is an acute infection distinguishable
from chronic infections, although this should not be
confused with several other acute lower respiratory tract
infections with well-recognised and distinguishable pat-
terns, such as bronchiolitis and bronchitis.
So, how can the field of pneumonia care and research
overcome the current lack of clarity concerning definition
and classification? One suggestion towards a definition of
pneumonia was to take a descriptive approach: explaining
anatomy and the respiratory ecosystem; describing what is
meant by ‘pneumonia’; listing the causative organisms
within the relevant context, and then proceeding to clin-
ical definition(s). There was a call to reach a consensus on
definitions of pneumonia in both resource-limited and
well-resourced settings.
Background
Pneumonia was first described by Hippocrates [5] (460–
370 BC). The first descriptions of its clinical and patho-
logical features were made 22 centuries later in 1819 by
Laennec [6] while Rokitansky [7] in 1842 was the first to
differentiate lobar and bronchopneumonia. During the
next 47 years at least 28 terms were used to identify
pneumonia [8], and by 1929 the total number of terms
listed in the Manual of the International List of Causes
of Death had grown to 94, with 12 sub-terms [9]. The
ICD-10 classification of diseases has removed some of
the historical descriptive terms and ‘pneumonia’ is listed
as the primary term in seven codes (J12–18) but it is
also a descriptive term in seven other codes relevant to
specific infectious and non-infectious aetiologies, times
of life and complications of diseases and procedures
[10]. ICD-10 codes usually include subcategories so
there are still many classifications for pneumonia. It is
also of note that ‘other acute lower respiratory infec-
tions’ comprise three other codes (J20–22) for acute
bronchitis, bronchiolitis and unspecified conditions.
Characterisation of the problem and its
magnitude
Harrison’s textbook of internal medicine defines pneu-
monia as an infection of the pulmonary parenchyma
caused by various organisms. It states that pneumonia is
not a single disease but a group of specific infections,
each with a different epidemiology, pathogenesis, pres-
entation and clinical course [11]. Harrison’s textbook de-
scribes the pathologic demarcation between lobar and
bronchopneumonia but concludes that the classification
of pneumonia is best based upon the causative micro-
organism. The textbook also describes that the specific
microbial aetiology remains unknown in more than a
third of patients, although it is common in children for a
blood culture to be the only test performed to provide a
specific diagnosis, which may only be positive in 5–10 %
of patients and up to 20 % in the most severely ill pa-
tients [12].
The lack of accepted, widely understood and com-
monly used definition(s) for pneumonia causes a funda-
mental problem where related but heterogeneous
pathologies and clinical phenotypes are poorly classified.
The lack of clear classification results in difficulty with
clinical decision making and a potential for poorly for-
mulated research. The magnitude of this problem is
most evident in the common inability to identify the in-
fectious organism(s) causing lung infection, necessitating
empiric antibiotic therapy. If a specific diagnosis could
be made, specific therapy could be provided which
would be of similar efficacy to empiric wide spectrum
therapy [13] and avoid millions of prescriptions of
broad-spectrum antibiotics and the associated risks of
antibiotic resistance.
The magnitude of the problem is less evident in the
field of pneumonia research. In a qualitative sense, the
problem may be distilled to a lack of homogeneity in
clinical and pathological phenotypes under investigation.
In studies of heterogeneous groups the research prob-
lems that may arise include an inability to determine
aetiology due to a limited range of methods; pathology
or microbiology with disparate patterns; and conflicting
results between studies that investigate risk factors, diag-
nostic methods or treatments. Heterogeneous groups
may result in disparate and unfocused studies, which fail
to target the most important types of pneumonia and
the most important questions, and make limited contribu-
tions. In epidemiologic terms, investigation of heteroge-
neous groups will, to a lesser or greater extent, threaten
the internal validity of studies. When heterogeneous
groups are studied, invalid estimates of effect occur due to
misclassification bias [14]. In the field of pneumonia
research, determining aetiology is a common difficulty.
For example, in the absence of specimens from the lung,
studies of aetiology may misclassify causality to organisms
detected in nasopharyngeal or sputum samples—in this
situation, misclassification bias occurs due to the difficulty
in accurately determining the aetiology of lung infection.
Epidemiologic studies are often designed to sample
participants from a target population so that the study
population is ‘representative’ of the target population.
However, taken to an extreme, the pursuit of representa-
tiveness can defeat the goal of identifying causal bio-
logical relations. In laboratory science, it is routine for
investigators to conduct experiments using animals with
characteristics selected to enhance the validity of the ex-
perimental work rather than to represent a target popu-
lation. Concerns about generalisability only become
important after it is accepted that the study results are
valid for the restricted group. Likewise, epidemiologic
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study designs are stronger if participant selection is
guided by the need to make a valid comparison, which
may call for severe restriction of eligibility to a narrow
range of characteristics, rather than attempting to make
the participants generally representative [14]. Statistically
speaking, selection of participants who are representative
of larger populations will often make it more difficult for
internally valid inferences to be made, due to misclassifi-
cation/heterogeneity of cases and an inability to control
for confounding by factors that vary within those
populations.
Minimising problematic
heterogeneity—definitions and classification of
pneumonia
To minimise the threats to the validity of research
outlined above, homogeneous study groups should be
selected with respect to clinical phenotype, pathology
and important confounders. Once effect estimates are
established by studies designed to maximise validity,
generalisation to other groups becomes simpler. To a
large extent, generalisation is a question of whether
the factors that distinguish populations from the
study group somehow modify the effect in question.
To answer this question, epidemiologic data will be of
help, but other sources of information such as patho-
physiology may also play an important role. In rela-
tion to pneumonia research, the internal validity of
studies will be improved if participants are more
homogenous with respect to factors associated with
the outcome. For example, when comparing antibac-
terial therapies in patients with pneumonia, the in-
ternal validity of the study will be improved if the
patient group is restricted to those with a proven bacterial
cause; antibacterial therapy cannot benefit patients with
viral pneumonia. The question of generalising study re-
sults to wider populations is a separate consideration. Het-
erogeneity of research participants is not always bad and
may be required when findings need to be generalised to
wider populations. The focus here is to illustrate the value
of studying homogenous groups when the current lack of
clarity in the classification of pneumonia results in a ten-
dency towards the inclusion of heterogenous groups.
Two examples of pneumonia research that have
substantially advanced the field illustrate the scientific
benefit of using restrictive criteria to study homogenous
patient subgroups. Firstly, between 1971 and 1981 a
collection of childhood pneumonia aetiology studies
using lung aspiration established, without a doubt, that
the aetiology in cases of substantial lobar pneumonia
(an homogenous subgroup) was bacterial in 30–80 %
of cases and pneumococcal in 10–50 % [15]. A more
recent study by McNally and colleagues [12] extensively
investigated children with severe or very severe
pneumonia with half having failed therapy (a homogenous
subgroup), and found that 18 % had more than one
aetiologic bacterial organism, thus establishing the para-
digm of co-infection in pneumonia.
To attain a homogeneous group of participants, re-
search studies must classify patients according to some
given criteria. Table 1 describes several systems for the
classification of pneumonia and also notes their advan-
tages and disadvantages. It is clear that all of the systems
of classification have significant deficiencies, primarily
relating to an inability to determine the aetiology of cases
of pneumonia, and substantial heterogeneity of aetiology,
phenotype and pathology. A theme also emerges where the
classification systems that are designed to guide clinical
care and treatment (e.g. the World Health Organization
[WHO], National Institutes of Health [NIH], and
Harrison’s), are the most prone to heterogeneity. Given
that empiric prescription of antibiotics and antimicrobial
resistance are such a concern and that pneumonia re-
search using definitions and classifications that lead to
substantial heterogeneity is relatively common, it would
appear that a fresh perspective would benefit the field.
A way forward
In the current setting of limited diagnostic methods, this
commentary proposes three points to ameliorate the dif-
ficulties with the definition and classification of pneumo-
nia. A working definition and approach to classification
is proposed to guide future research and, to a lesser
extent, clinical care. Each of the three points includes a
qualifying statement that, if heeded, should benefit the
field of research.
One
Pneumonia should be defined as an acute infection of
the lung parenchyma by one or co-infecting pathogens,
but excluding the well-defined condition of bronchiolitis,
the primary cause of which is almost always a viral
agent.
Two
It should be accepted that defining pneumonia as a
group of specific (co)infections with different character-
istics is an ideal, but this ideal currently has limited use
because the identification of aetiologic organisms in indi-
viduals is often not possible. This statement is qualified,
however, in that the classification of pneumonia into spe-
cific phenotypes using current or potential methods
should be carefully considered when designing research
studies. The study of more homogenous phenotypes is
likely to provide better evidence for clinical care and more
clear inference in research. Research should continue
into the aetiologic diagnosis of pneumonia, as better
understanding of aetiology and pathogenesis will improve
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our ability to prevent pneumonia and provide specific
therapy.
An implication of point two is that research should de-
fine questions that can be answered in a valid manner.
The inclusion of more homogenous phenotypes will
minimise confounding and bias. Emphasis on inclusion
of patient groups that are representative of wide popula-
tions may not advance the field as wished. It may be that
a greater focus on studying high-risk groups, specific ae-
tiologies, very severe cases, patients with consolidation,
narrow age groups, etc., may provide a greater yield of
knowledge to support targeted interventions. Thus, clini-
cians and public health researchers should consider how
best to function in the arena of pneumonia treatment
guidelines and policy as well as that of the biology,
pathology, therapy and prevention of pneumonia in
subgroups and subtypes of pneumonia. It needs to be
considered how these two domains—public health policy
for the treatment and prevention of pneumonia, and
research to answer specific questions of pathogenesis,
diagnosis, treatment and prevention—can better interact.
Three
Classifications of pneumonia in clinical care and re-
search will be limited by the means available but can be
made more specific using the approaches described in
Table 1, and combinations thereof (Table 1 is not a
complete list of all available approaches). This statement
is qualified by the knowledge that vaccine probe studies
are potentially powerful instruments for the investigation
of pneumonia aetiology and pathogenesis and inves-
tigators should take the opportunity to conduct such
studies. Vaccine probe studies allow classifications of
pneumonia which are impossible by any other means. A
Table 1 Methods of pneumonia classification and their advantages and disadvantages
Classification Description of classification Advantages Disadvantages
WHO [16] Pneumonia: Age 2–59 months with cough
or difficult breathing and fast breathing
and/or chest in-drawing.
Severe pneumonia: pneumonia with any
danger sign
Clinical: simple programmatic
implementation to guide treatment
Research: easy to enrol patients and
findings directly generalisable
Clinical: no definition of aetiology,
high levels of empiric antibiotic therapy
Research: highly heterogeneous including
viral, bacterial and other aetiologies
NIH [17] Community/hospital-acquired, health care-
associated, aspiration, and atypical (caused
by Legionella, Mycoplasma, Chlamydia)
Clinical: simple, guides empiric therapy
Research: easy to enrol patients,
findings directly generalisable
Clinical: little definition of aetiology or
pathology, empiric antibiotic therapy
Research: heterogeneous phenotypes
Pathology Acute inflammation of lung parenchyma,
inflammatory alveolar infiltrate
Clinical: resolve cases of difficult
diagnosis
Research: highly homogenous
Clinical: limited availability and relevance
Research: difficult to enrol patients
ICD-10 Uses clinical and laboratory diagnoses with
known or unknown aetiology and many
potential classifications
Clinical: not used clinically, primarily
used for audit and administration
Research: Analyses of clinical databases
Clinical: limited relevance
Research: little definition of aetiology,
heterogeneous, not systematic
Harrison’s
textbook [11]
Infection of pulmonary parenchyma by
various pathogens, not a single disease.
Terms lobar or bronchopneumonia not
recommended. Clinical categories:
community-acquired, nosocomial, aspiration
Clinical: encourages aetiologic
diagnosis and guides empiric therapy
Research: aetiologic diagnosis provides
homogeneity, findings are directly
generalisable
Clinical: difficult to confirm aetiology,
substantial empiric antibiotic therapy
Research: difficult to enrol patients with a
single aetiology, clinical categories give
heterogeneous aetiology and phenotype
Clinical Features: Age, acute/chronic, bronchiolitis,
nosocomial, recurrent, comorbidity, HIV-
related, complications, severity, mortality
Clinical: multiple inputs to guide
treatment
Research: may be easy to enrol
patients, flexible, may define
‘important’ subgroups
Clinical: no aetiology, empiric therapy
Research: heterogeneity, not standardised,
difficult to generalise
Chest radiograph Interstitial/alveolar/lobar/air bronchogram
WHO: dense, fluffy consolidation of entire
lung or portion of a lobe; often with air
bronchograms and possibly pleural effusion
[15]
Clinical: supports viral or bacterial
aetiology, identifies complications
Research: some homogeneity and
alignment with aetiology, standardised
Clinical: availability, time, expense
Research: some difficulty enrolling patients,
heterogeneous aetiology, unable to detect
co-infection
Ultrasound Subpleural consolidation, B-lines, pleural line
abnormalities, pleural effusion, air
bronchogram
Clinical: fast, no radiation, for
complications
Research: simpler than radiograph,
some homogeneity
Clinical: availability, no aetiology
Research: detection in non-peripheral lung,
not standardised, heterogeneity
Microbiology Culture of blood, lung/pleural aspiration, BAL
Bacterial – viral – co-infection
Clinical: directs specific therapy
Research: homogenous
Clinical: slow, limited detection
Research: difficult to enrol patients
Serology/antigen Blood, urine, NPS (Legionella, S. pneumoniae) Rapid, pathogen-specific Range/sensitivity of tests, misclassification
CRP High CRP correlates with bacterial aetiology Increased sensitivity for bacterial
disease
Optimal threshold unclear, no aetiology
BAL Broncho-alveolar lavage, CRP C-reactive protein, NPS Nasopharyngeal sample
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classic vaccine probe study was able to define the entity
of ‘viral-associated pneumococcal pneumonia’ providing
a substantial advance in our understanding of pneumonia
pathogenesis and aetiology [18].
In summary, refining the definition and classification
of pneumonia is a formidable task as multiple terms are
used in multiple fields of medical practice and research.
The dangers of poor classification of pneumonia are
widespread empiric antibiotic therapy and heterogeneous
groups in research, which have a tendency to influence
the construction of research questions and studies. As a
result, these research questions and studies may not
provide clear answers. The aim of this commentary is to
stimulate debate towards consensus classifications for
clinical terminology, separating bronchiolitis from pneu-
monia, examining the value of the community- and
hospital-acquired classification, and purposeful refinement
of classifications based on microbiology, aetiology,
radiology, severity, complications, important age groups
and subgroups. In the interim, better ways to determine
the aetiology of pneumonia need to be sought, and re-
searchers should consider the benefits of using methods
of classification to provide more homogeneous groups,
the study of which is likely to provide clearer answers to
research questions.
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Note from the Editor: Professor Keith Grimwood
The commentary provided by Dr Mackenzie summarises nicely the
challenges associated with arriving at a universally accepted definition of
pneumonia, which addresses different patient groups, aetiologies and
underlying disease mechanisms. At present, a solution to this problem is
not forthcoming and as a result both clinical practice and research into
pneumonia is compromised. The difficulty clinicians encounter in confidently
identifying the causative agents of suspected pneumonia cases can lead to
over-prescribing of broad-spectrum antimicrobial agents, which contributes
to increasing health costs, risks adverse effects and promotes further
antimicrobial resistance. Similarly, misclassification of pneumonia limits high
quality epidemiological and clinical research. Sadly, the methods outlined are
tried, but not necessarily trusted techniques for improving the diagnosis and
classification of pneumonia. Even the recent modifications to the WHO
classification of childhood pneumonia fail to address the problems of poor
diagnostic specificity where it is not possible to reliably differentiate between
bacterial and non-bacterial pneumonia, or to always differentiate pneumonia
from malaria, dehydration or acute central nervous system disorders.
Dr Mackenzie’s article is a timely “call to arms” for clinicians and scientists to
formulate a commonly agreed definition of pneumonia that will allow
research to be conducted on well-defined patient groups to help optimise
diagnostic strategies, develop better tests to determine aetiology, rationalise
treatment and improve overall patient and community health outcomes.
Much needs to be done and further commentary and debate is invited.
Author details
1Basse Field Station, Medical Research Council Unit, The Gambia, c/o MRC
Unit, PO Box 273, Banjul, Gambia. 2Murdoch Childrens Research Institute,
Melbourne, Australia. 3London School of Hygiene and Tropical Medicine,
Keppel St, London, UK.
Received: 14 December 2015 Accepted: 5 August 2016
References
1. O'Grady KF, Torzillo PJ, Frawley K, Chang AB. The radiologic diagnosis of
pneumonia in children. Pneumonia. 2014;5:38–51.
2. Aston SJ. The role of rapid diagnostic tests in managing adults with
pneumonia in low-resource settings. Pneumonia. 2014;5:8–17.
3. Rylance J, Waitt P. Pneumonia severity scores in resource poor settings.
Pneumonia. 2014;5:30–7.
4. Rasanen J, Gavriely N. Childhood pneumonia screener: a concept.
Pneumonia. 2014;5:52–8.
5. Hippocrates. The genuine works of Hippocrates, 1:324. In: Translated from
the Greek with a preliminary discourse and annotations by Francis Adams.
London: Sydenham Society; 1849.
6. Laennec RT. A treatise on the diseases of the chest and on mediate
auscultation. In: Translated from the 3rd French ed. by J. Forbes, with notes
of Prof. Andral from the 4th ed. New York: SS & Wm. Wood; 1838.
7. Rokitansky C. Inflammations of the lungs (pneumoniae). In: Manual of
Pathological Anatomy. London: Sydenham Society; 1852.
8. Wells EF. Introduction to study of pneumonic fever. III. Nature. JAMA 1889;
•••:332. http://dx.doi.org/10.1001/jama.1889.02400870008001a.
9. United States Bureau of the Census. Manual of the international list of
causes of death: based on the fourth decenial revision by the International
Commission, Paris, October 16 to 19, 1929. Washington: Government
Printing Office; 1931.
10. ICD-10 Version. 2016. World Health Organization website; Available
from: http://apps.who.int/classifications/icd10/browse/2016/en.
Accessed 9 Dec 2015.
11. Levison ME. Pneumonia, Including Necrotizing Pulmonary Infections
(Lung Abscess). In: Braunwald E, Fauci AS, Hauser SL, Longo DL, Kasper DL,
Jameson JL, editors. Harrison’s principles of internal medicine. 15th ed.
New York: McGraw-Hill; 2001. p. 1475–84.
12. McNally LM, Jeena PM, Gajee K, Thula SA, Sturm AW, Cassol S, et al.
Effect of age, polymicrobial disease, and maternal HIV status on treatment
response and cause of severe pneumonia in South African children: a
prospective descriptive study. Lancet. 2007;369:1440–51. PMID:17467514,
http://dx.doi.org/10.1016/S0140-6736(07)60670-9.
13. van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Bronsveld W,
Jansen HM, et al. Comparison between pathogen directed antibiotic
treatment and empirical broad spectrum antibiotic treatment in patients
with community acquired pneumonia: a prospective randomised study.
Thorax. 2005;60:672–8. PMID:16061709, http://dx.doi.org/10.1136/thx.2004.
030411.
14. Rothman KJ, Greenland S, Lash TL. Validity in Epidemiologic Studies, Ch 9.
In: Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. 3rd ed.
Philadelphia: Lippincott Williams & Wilkins; 2008.
15. World Health Organization Pneumonia Vaccine Trial Investigators’ Group.
Standardization of interpretation of chest radiographs for the diagnosis of
pneumonia in children. World Health Organization website; Available from
http://www.who.int/vaccines-documents/. Accessed 3 Oct 2004.
16. World Health Organisation. Revised WHO classification and treatment of
childhood pneumonia at health facilities - Evidence Summaries. Geneva:
World Health Organisation; 2014. World Health Organisation website;
Available from http://www.who.int/maternal_child_adolescent/documents/
child-pneumonia-treatment/en/.
17. Types of pneumonia. NIH website; Available from http://www.nhlbi.nih.gov/
health/health-topics/topics/pnu/types. US Department of Health & Human
Services; March 1, 2011. Accessed 11 Dec 2015.
18. Madhi SA, Klugman KP, Vaccine Trialist Group. A role for Streptococcus
pneumoniae in virus-associated pneumonia. Nat Med. 2004;10:811–3.
PMID:15247911, http://dx.doi.org/10.1038/nm1077.
Mackenzie Pneumonia  (2016) 8:14 Page 5 of 5
